You are offline. Saved alerts are still available. Live updates resume when you reconnect.
Reading a stock page
- The tabs show the price chart, results, shareholding, events and news for this one company.
- The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
- Every figure names its source. "Official" means it came from NSE or BSE filings.
- Use the star to watch the stock, or Add to portfolio to record a trade.
🎯 Buy It or Not? — Complete Intraday to Long-Term Decision Report for INDSWFTLAB (BSE)
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
52
ISA Signal Score: Neutral
Trend60
Momentum25
52-week range74
Volume38
Risk43
Fundamentals72
Working for it
- Price is above its 200-day average (long-term uptrend)
- 50-day average is above the 200-day average
- 50-day average is rising
- Low debt
Working against it
- Price is below its 20-day average
- Price is below its 50-day average
- MACD is negative and weakening
Red flags
- Very volatile: it moves about 7.2% on a typical day
At a glance
QualityWeakROE 0.0%, ROCE 52.8%, almost no debt
GrowthNot knownNeeds at least 3 years of results. More years load on later visits.
ValuationNo earningsP/E cannot be worked out while the company makes a loss.
MomentumStrongAbove its 200-day average, beat NIFTY 50 by 247.5 points
RiskHighSwings 62% a year, fell up to 21% from a peak, beta 0.59
Smart Investor Tips: INDSWFTLAB
Caution Warranted (Trend or Balance-Sheet Headwinds)Actionable Insights & Positives
- Pullback within a long-term uptrend: holding above the 200-day average (Rs 231.08) while digesting gains below the 50-day average (Rs 369.97).
- Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.
Risk Checks & Things to Verify
- Reported a net loss in FY24. Turnaround stories carry higher execution risk.
- High 30-day annualized volatility (68%). Keep initial position sizes smaller and use wider stop-review levels.
BSE Authentic Bhavcopy & Cross-Exchange Check No API Key
Algorithmic Momentum Prediction & Optimal Entry PriceWEAK / REDUCE ON BOUNCES (Score 31/100)
Weak trend, debt overhang, or distribution. Avoid fresh buying until price reclaims 50-DMA (Rs 369.97). If already held, protect capital if it breaks below Rs 205.04 or trim near resistance Rs 426.00.
| Optimal Support area | Tranche 1 (50%) | Tranche 2 (50%) | Risk level / Review | Level 1 (Swing) | Level 2 (Breakout) | Risk : Reward |
|---|---|---|---|---|---|---|
| Rs 317.30 – Rs 330.20 Ideal ~Rs 323.75 |
Rs 330.20 | Rs 317.30 | Rs 205.04 ATR 7.2% |
Rs 537.43 | Rs 679.88 | 1 : 1.8 RSI 28 · Vol 0.79x |
Live Candlestick & TradingView Chart (INDSWFTLAB)
MARKET CLOSED - EOD SNAPSHOTKey figures
P/E4.6sector median 44.6
P/B2.09xprice / book value
EPSRs 71.24grew 783.9% a year
Dividend yield-from saved dividend events
Debt to equity0.02xmore cash than debt
Sales growth6.1%a year over 1 years
Profit growth-yearly, needs 2+ years
Operating margin50.0%net margin 0.0%
Company Debt, Borrowings & Cash Flow Health
Total Debt / Loans
Rs 16.6 Cr
Reduced Rs 845 Cr YoY
Cash & Bank Balances
Rs 432 Cr
Liquid cash & equivalents
Net Debt (Loans − Cash)
Net Cash Rs 415 Cr
Debt-free on net basis
Debt to Equity & Interest Cover
0.02x D/E
Interest cover: 12.4x EBIT
Operating Cash Flow (OCF)
Rs -181 Cr
Cash generated from operations
Free Cash Flow (FCF)
Rs -225 Cr
After Capex of Rs 44.5 Cr
About IND-SWIFT LABORATORIES
HealthcareMarket capRs 1,951 CrSmall cap · 5.91 Cr shares
First listed02 Jul 1997BSE not available · NSE 02 Jul 1997
Face valueRs 10
Book valueRs 157.64Price is 2.1x book value
ROE0.0%weak, below 8%
ROCE67.1%good, above 15%
Profile completeness7 of 8Missing: description · ratios as of FY2024
Shareholding
Promoters and group 42.93%, public 57.07%, as on 30 Sep 2026. Holder names and history
Day range327.00 to 336.75Open 335.95
52-week high426.00
-22.5% from high (30 Oct 2026)
52-week low87.00
+279.5% from low (09 Dec 2025)
Volume19,105
0.3x the 20-day average
RSI (14)41
neutral
Volatility (30d)68.4%annualised
Returns
1W-8.2%
1M-6.3%
3M-0.9%
6M+143.2%
1Y+245.4%
YTD+274.4%
3Y a year+51.7%
5Y a year+35.0%
Against the NIFTY 50
| Period | INDSWFTLAB | NIFTY 50 | Difference |
|---|---|---|---|
| 1M | -6.3% | +11.5% | -17.8 pts |
| 3M | -0.9% | +5.3% | -6.2 pts |
| 6M | +143.2% | +7.9% | +135.3 pts |
| 1Y | +245.4% | -2.1% | +247.5 pts |
Risk over the past year
Volatility62%high
Deepest fall-20.8%from a peak
Beta0.59moves less than the index
Best day+20.0%11 Aug 2026
Worst day-10.1%30 Oct 2026
Up days51%of sessions
🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition
Piotroski F-Score: 5 / 9 · Solid Financial Health
3-Step DuPont ROE Identity:
Balanced Profitability & Efficiency
Net Margin: 0.0%
×
Asset Turnover: 1.10x
×
Equity Multiplier: 1.25x
=
ROE 0.0%
⚠ Positive Net Profit (PAT > 0)
Rs 0 Cr
⚠ Positive Operating Cash Flow (OCF > 0)
Rs -181 Cr
⚠ High Cash Conversion (OCF >= 85% of PAT)
N/A
✓ Improving Return on Assets (ROA YoY)
0.0% vs 0.0%
✓ Conservative / Decreasing Debt-to-Equity
0.02x (prev 1.26x)
✓ Healthy Balance Sheet Asset Coverage
5.27x
⚠ Institutional Return on Equity (ROE >= 14%)
0.0%
✓ Stable / Expanding Profit Margin YoY
0.0% vs 0.0%
✓ Asset Turnover Efficiency (Sales / Assets)
1.10x
Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration)
| Rs crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales / Revenue | 1.41 | 138 | 153 | 159 | 151 | 170 | 191 | 240 |
| Sales QoQ % | -48.0% | +9687.2% | +10.9% | +3.9% | -5.0% | +12.6% | +12.4% | +25.7% |
| Operating Profit | -8.81 | -10.0 | 3.00 | 7.00 | 4.00 | 21.0 | 35.0 | 45.0 |
| Operating Margin (OPM %) | -624.8% | -7.2% | 2.0% | 4.4% | 2.6% | 12.4% | 18.3% | 18.8% |
| Net Profit (PAT) | 4.64 | 222 | 9.00 | 8.00 | 10.0 | 15.0 | 25.0 | 34.0 |
| Profit QoQ % | +1350.0% | +4684.5% | -95.9% | -11.1% | +25.0% | +50.0% | +66.7% | +36.0% |
| Profit YoY % | -78.6% | -36.5% | +45.4% | +2400.0% | +115.5% | -93.2% | +177.8% | +325.0% |
| Net Margin % | 329.1% | 160.9% | 5.9% | 5.0% | 6.6% | 8.8% | 13.1% | 14.2% |
Sales and profit
Sales growth+6.1%a year, 1Y
Profit growth-a year, 1Y
EPS growth+783.9%a year, 1Y
Avg ROE0.0%2 years
Profit and loss
| Rs crore | FY23 | FY24 |
|---|---|---|
| Sales | 1,207 | 1,281 |
| Sales growth | - | +6.1% |
| Operating profit | 203 | 641 |
| Operating margin | 16.8% | 50.0% |
| Other income | 33.5 | 45.4 |
| Interest | 92.2 | 51.1 |
| Depreciation | 57.4 | 53.3 |
| Profit before tax | 86.5 | 582 |
| Tax rate | 44.7% | 26.0% |
| Net profit | 0 | 0 |
| Profit growth | - | - |
| Net margin | 0.0% | 0.0% |
| EPS (Rs) | 8.06 | 71.24 |
Balance sheet
| Rs crore | FY23 | FY24 |
|---|---|---|
| Equity (net worth) | 682 | 931 |
| Borrowings | 862 | 16.6 |
| Cash | 18.2 | 432 |
| Total assets | 1,824 | 1,165 |
| Debt to equity | 1.26x | 0.02x |
Debt, Loans, Cash Flow & Working Capital
| Rs crore | FY23 | FY24 |
|---|---|---|
| Operating Cash Flow (OCF) | 195 | -181 |
| Capital Expenditure (Capex) | 12.8 | 44.5 |
| Free Cash Flow (FCF = OCF - Capex) | 182 | -225 |
| OCF / Net Profit Conversion | - | - |
| Total Borrowings / Loans | 862 | 16.6 |
| Cash & Bank Balances | 18.2 | 432 |
| Trade Receivables (Cr) | 505 | 169 |
| Receivable Days | 152.77x | 48.19x |
| Inventories (Cr) | 439 | 10.5 |
| Inventory Days | 132.60x | 2.98x |
Returns on capital
| Rs crore | FY23 | FY24 |
|---|---|---|
| ROE | 0.0% | 0.0% |
| ROCE | 12.3% | 52.8% |
| Interest cover | 1.94x | 12.38x |
Compared with its sector Pharma & Healthcare
| Stock | Price | Day | 1 year | Mkt cap (Cr) | P/E | P/B | ROE | Net margin |
|---|---|---|---|---|---|---|---|---|
| ALIVUSALIVUS LIFE SCIENCES LIMITED | 1,449.85 | +0.3% | - | 17,768 | 37.7 | 7.6 | 20.2% | 20.6% |
| CAPLIPOINTCAPLIN POINT LABORATORIES LTD. | 2,085.40 | -0.0% | - | 15,839 | 34.6 | 6.8 | 19.7% | 27.0% |
| ASTRAZENASTRAZENECA PHARMA INDIA LTD. | 6,120.45 | +1.9% | - | 15,301 | 94.7 | 21.5 | 22.7% | 12.5% |
| AARTIPHARMAarti Pharmalabs Limited | 1,024.80 | +1.3% | - | 9,287 | 42.8 | 5.3 | 12.3% | 11.7% |
| BLUEJETBlue Jet Healthcare Limited | 516.80 | -0.2% | - | 8,964 | 54.7 | 10.6 | 19.4% | 23.0% |
| CIPLACIPLA LTD. | 1,416.00 | -0.3% | - | - | 29.5 | - | - | 13.7% |
| ALKEMAlkem Laboratories Limited | 5,145.00 | -1.1% | - | - | 26.7 | - | 17.0% | 16.0% |
| DIVISLABDIVIS LABORATORIES LTD. | 11,178.00 | +1.0% | - | - | 115.6 | - | 15.3% | 24.3% |
| WOCKPHARMAWOCKHARDT LTD. | 2,186.60 | +7.9% | - | - | - | - | - | - |
| RUBICONRUBICON RESEARCH LIMITED | 1,726.00 | +3.9% | - | - | - | - | - | - |
| APOLLOHOSPAPOLLO HOSPITALS ENTERPRISE LT | 8,744.80 | -0.8% | - | - | 64.8 | - | 21.1% | 7.9% |
| RAINBOWRainbow Children's Medicare Li | 1,241.45 | -1.3% | - | - | - | - | - | - |
| Sector median | - | 44.6 | 7.6 | 17.0% |
Today: 15 minute chart and signal
Analysis and next-session reading
Signals
Price is below its 50-day average
20-day average is below the 50-day (short-term downtrend)
Price is above its 200-day average (long-term uptrend)
RSI 41: neutral
When is a good price?
The price is in the upper half of its 1-year range and is lower than it was on 23% of days in the past year.
Support (prices below today's)
| 20-day low | 321.20 | -2.7% |
| 60-day low | 317.30 | -3.9% |
| 200-day average | 231.08 | -30.0% |
| 52-week low | 87.00 | -73.7% |
Resistance (prices above today's)
| 50-day average | 369.97 | +12.0% |
| 20-day high | 426.00 | +29.0% |
| 60-day high | 426.00 | +29.0% |
| 52-week high | 426.00 | +29.0% |
Zones buyers often watch
| Lower quarter of the 1-year range | 87.00 to 171.75 | Historically the cheapest part of the past year. |
| Pullback of 10% to 20% from the high | 340.80 to 383.40 | A common area for dips inside an uptrend. |
| Around the 200-day average | 224.15 to 238.02 | Long-term trend line, often watched as support. |
Moving averages and momentum
| Indicator | Value | Reading |
|---|---|---|
| 20-day average | 354.46 | Price is 6.8% below |
| 50-day average | 369.97 | Price is 10.8% below |
| 200-day average | 231.08 | Price is 42.9% above |
| RSI (14) | 41 | Neutral |
| MACD (12, 26, 9) | -7.04 | Below its signal line (momentum fading) |
| Volatility (30d) | 68.4% | High yearly swings |
Support and resistance
R2341.07
R1335.63
Pivot331.32
S1325.88
S2321.57
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| 2026-11-19 | 335.95 | 336.75 | 327.00 | 330.20 | -1.70% | 19,105 |
| 2026-11-18 | 335.80 | 339.00 | 325.25 | 335.90 | +1.02% | 48,171 |
| 2026-11-17 | 339.55 | 345.40 | 330.00 | 332.50 | -4.90% | 51,479 |
| 2026-11-16 | 371.65 | 371.65 | 344.00 | 349.65 | -3.21% | 22,772 |
| 2026-11-13 | 362.95 | 363.00 | 350.85 | 361.25 | +0.49% | 17,778 |
| 2026-11-12 | 363.25 | 366.75 | 357.80 | 359.50 | -0.75% | 23,682 |
| 2026-11-11 | 352.00 | 364.90 | 350.00 | 362.20 | +3.63% | 30,812 |
| 2026-11-09 | 335.95 | 352.75 | 332.45 | 349.50 | +3.62% | 30,347 |
| 2026-11-06 | 358.35 | 361.60 | 343.40 | 347.60 | -2.48% | 20,758 |
| 2026-11-05 | 382.40 | 382.40 | 355.00 | 356.45 | -4.09% | 71,060 |
| 2026-11-04 | 347.00 | 373.60 | 346.95 | 371.65 | +8.43% | 34,438 |
| 2026-11-03 | 356.50 | 367.85 | 338.40 | 342.75 | -3.23% | 51,733 |
| 2026-11-02 | 372.95 | 375.70 | 347.40 | 354.20 | -3.59% | 80,313 |
| 2026-10-30 | 417.85 | 426.00 | 353.45 | 367.40 | -10.14% | 212,154 |
| 2026-10-29 | 380.00 | 424.15 | 373.90 | 408.85 | +7.75% | 194,553 |
| 2026-10-28 | 378.10 | 381.55 | 364.15 | 379.45 | +3.04% | 34,045 |
| 2026-10-27 | 332.90 | 375.00 | 332.90 | 368.25 | +8.97% | 60,848 |
| 2026-10-26 | 321.20 | 343.75 | 321.20 | 337.95 | +3.10% | 30,124 |
| 2026-10-23 | 347.00 | 348.45 | 322.05 | 327.80 | -5.31% | 78,442 |
| 2026-10-22 | 336.10 | 349.65 | 336.10 | 346.20 | +1.15% | 17,523 |
| 2026-10-21 | 352.40 | 365.00 | 337.30 | 342.25 | -2.88% | 68,508 |
| 2026-10-19 | 359.45 | 364.15 | 350.50 | 352.40 | -1.87% | 14,605 |